Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have earned a consensus recommendation of “Hold” from the nine analysts that are currently covering the stock. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $26.00.
Several equities analysts recently weighed in on LXRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday, April 5th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 17th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday, February 8th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective (up from $26.00) on shares of Lexicon Pharmaceuticals in a research note on Wednesday, March 1st. Finally, Citigroup Inc lifted their price objective on shares of Lexicon Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, March 7th.
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down 0.80% during trading on Tuesday, reaching $14.88. The company’s stock had a trading volume of 274,432 shares. Lexicon Pharmaceuticals has a 12 month low of $11.52 and a 12 month high of $19.62. The firm’s market cap is $1.55 billion. The stock’s 50 day moving average price is $14.88 and its 200-day moving average price is $15.35.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Friday, March 3rd. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.20. The company earned $23 million during the quarter, compared to analysts’ expectations of $15.56 million. Lexicon Pharmaceuticals had a negative net margin of 11.87% and a negative return on equity of 9.46%. Lexicon Pharmaceuticals’s quarterly revenue was down 81.9% on a year-over-year basis. During the same period last year, the company posted $0.76 earnings per share. Equities analysts predict that Lexicon Pharmaceuticals will post ($1.49) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) Receives $26.00 Average PT from Analysts” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/04/21/brokerages-set-lexicon-pharmaceuticals-inc-lxrx-target-price-at-26-00-updated.html.
Several large investors have recently added to or reduced their stakes in LXRX. BlackRock Inc. raised its stake in Lexicon Pharmaceuticals by 478.8% in the third quarter. BlackRock Inc. now owns 18,932 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 15,661 shares during the period. Numeric Investors LLC purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at about $295,000. Boston Advisors LLC purchased a new stake in Lexicon Pharmaceuticals during the third quarter valued at about $397,000. A.R.T. Advisors LLC bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth $475,000. Finally, Piermont Capital Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the third quarter worth $642,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.